A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

President Donald Trump signed an executive order on Monday aimed at slashing prescription drug prices in the U.S. that could ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Eventually, it was proven that Mounjaro is more affective than Wegovy in terms of weight loss, with 32 per cent of ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

A doctor has issued a warning about a less documented side effect of Ozempic that can apparently have a long-term health ...

Lilly's study showed that more patients treated with Zepbound had reductions in body weight of at least 10%, 15%, 20%, and 25% than those treated with Wegovy, while they also achieved a greater ...